New combination therapy improves survival in non-small cell lung cancer

Aiyappan, Vinod
March 2007
Thorax;Mar2007, Vol. 62 Issue 3, p259
Academic Journal
The article discusses A. Sandler and colleagues' study of the effectiveness of paclitaxel-carboplatin alone or with bevacizumab in treating patients with non-small-cell lung cancer. The study revealed significant survival benefits of adding bevacizumab to the combination therapy in a select group of patients, at the risk of increased treatment-related deaths.


Related Articles

  • Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens. Nannan Panday, V.R.; van Warmerdam, L.J.C.; Huizing, M.T.; ten Bokkel Huinink, W.W.; Vermorken, J.B.; Giaccone, G.; Veenhof, C.H.N.; Schellens, J.H.M.; Beijnen, J.H. // Clinical Drug Investigation;1998, Vol. 15 Issue 4, p327 

    Carboplatin is a frequently used antitumour agent recommended to be administered according to the Calvert formula: dose = AUC × (GFR+25), where GFR is the glomerular filtration rate as measured by Cr-EDTA clearance and AUC is the targeted area under the carboplatin concentration versus time...

  • Cisplatin + pemetrexed as first-line therapy for advanced NSCLC.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p5 

    The article discusses research on the use of combined cisplatin and pemetrexed for advanced nonsquamous non-small cell lung cancer (NSCLC). It references the study "Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer," by R....

  • An open, multi-centre, phase II clinical trial to evaluate the efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Chao, Y.; Li, C. P.; Chao, T. Y.; Su, W. C.; Hsieh, R. K.; Wu, M. F.; Yeh, K. H.; Kao, W. Y.; Chen, L. T.; Cheng, A. L. // British Journal of Cancer;7/17/2006, Vol. 95 Issue 2, p159 

    The aim of the study was to evaluate the response rate and safety of weekly paclitaxel (Taxol®) combination chemotherapy with UFT (tegafur, an oral 5-fluorouracil prodrug, and uracil at a 1 : 4 molar ratio) and leucovorin (LV) in patients with advanced gastric cancer. Patients with...

  • Phase I study of paclitaxel, carboplatin and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Yasushi Ono; Mitsunori Hino; Yuka Ueda; Ryoko Kamizuru; Masatoshi Omata; Takashi Uehara; Yosuke Tanaka; Tomoyuki Soma; Shoji Kudoh // Medical Oncology;Dec2007, Vol. 24 Issue 4, p402 

    Abstract Objective  We conducted a phase I study of paclitaxel (PTX), carboplatin (CBDCA), and UFT in chemo-naive patients with advanced non-small cell lung cancer (NSCLC). Method  Twenty-one chemo-naive patients with advanced NSCLC were enrolled. The study was conducted as a...

  • A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer. Hokita, Shuichi; Aikou, Takashi; Miyazono, Futoshi; Ishigami, Sumiya; Aridome, Kuniaki; Maenohara, Shigeho; Saihara, Tetsushi; Suenaga, Kuniaki; Nomura, Hidehiro; Maeda, Satoshi; Takatori, Hiroyuki; Arima, Hideo; Uchikado, Yasuto; Natsugoe, Shoji; Takao, Sonshin // Cancer Chemotherapy & Pharmacology;Jun2006, Vol. 57 Issue 6, p736 

    The aim of the current study was to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of a combination of paclitaxel and S-1 in patients with advanced gastric cancer. Fifteen patients were enrolled. The dose for S-1 was set at 80 mg/m2/day (days 1–14), while...

  • Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group. Masuda, Norikazu; Taguchi, Tetsuya; Nakayama, Takahiro; Shiba, Eiichi; Watatani, Masahiro; Kurebayashi, Junichi; Takatsuka, Yuichi; Sakamoto, Junichi; Noguchi, Shinzaburo // Cancer Chemotherapy & Pharmacology;May2008, Vol. 61 Issue 6, p989 

    The combination of capecitabine and paclitaxel (XP) has demonstrated synergistic antitumor activity in preclinical models. Three-weekly XP regimens have demonstrated excellent efficacy in phase II and III trials in metastatic breast cancer. We conducted a dose-finding study to identify the...

  • Abraxis BioScience Inc.  // BioWorld Today;8/4/2009, Vol. 20 Issue 148, p7 

    The article reports on the release by Abraxis BioScience Inc. of Phase II results which show evidence of antitumor activity in advanced non-small-cell lung cancer patients receiving first-line treatment regimens of Abraxane in combination with carboplatin. The results, presented at the 2009...

  • Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients. Herrera, Zaima; Ramos, Tania // Cancer Immunology, Immunotherapy;Jul2014, Vol. 63 Issue 7, p737 

    Cancer vaccines contain tumor antigens in a pro-inflammatory context with the purpose to generate potent antitumor immune responses. However, tumor cells develop different immunosuppressive mechanisms that limit the effectiveness of an anticancer immune response. Therefore, therapeutic vaccine...

  • Recent Advances with Topotecan in the Treatment of Lung Cancer. O'Brien, Mary; Eckardt, John; Ramlau, Rodryg // Oncologist;Oct2007, Vol. 12 Issue 10, p1194 

    Topotecan is a semisynthetic derivative of camptothecin that specifically targets topoisomerase I. It has well-established antineoplastic properties and has been successfully combined with other antineoplastic agents with activity dependent on DNA disruption, such as cisplatin and etoposide....


Read the Article


Sign out of this library

Other Topics